Kamada (KMDA) Q1 2025 Earnings Call May 14, 2025 08:30 AM ET Company Participants Brian Ritchie - Managing DirectorAmir London - Chief Executive OfficerChaime Orlev - Chief Financial OfficerAnnabel Samimy - Managing Director Conference Call Participants Jim Sidoti - Analyst Operator Greetings, and welcome to the Comida First Quarter twenty twenty five Earnings Conference Call. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. As a re ...

智通财经APP获悉，日前，长江证券发布燃气行业2024年报及2025年一季报研究报告。报告中指出，虽 然受天然气需求偏弱影响，燃气板块2024年及2025年一季度业绩表现偏弱，但城市燃气依然具备一定的 α投资价值。港股城市燃气公司一直相对稳定的分红派息，股息回报率较为可观，且中长期而言具备优 于水电的成长性。其中，天伦燃气(01600)逆势提升分红派息比例，以6.00%的高股息率强势领跑，远超 行业平均5%的水平，凸显公司强劲的现金流实力和回馈股东的坚定承诺，成为当下防御性配置的优质 之选。 长江证券提到，2024 年底天然气表观消费量增速显著放缓，主因系暖冬因素压制天然气需求。2025年 一季度，暖冬影响延续，天然气需求疲软，一季度我国天然气表观消费量1057.50 亿立方米，同比减少 2.2%。虽然当前来看天然气需求增长存在一定压力，但地区差异化的表现同样值得关注，随着国家持 续推进东南沿海产业向中西部转移，中西部地区的天然气消费量增速将会得到一定支撑。 长江证券认为，港股城市燃气公司一直相对稳定的分红派息，股息回报率较为可观，且中长期而言具备 优于水电的成长性。从港股板块整体表现来看，2024 年港股燃 ...

证券研究报告 | 行业周报 gszqdatemark 2025 05 11 年 月 日 食品饮料 周观点：统一 Q1 盈利亮眼，把握结构性α 投资建议：1、白酒：强化内功，蓄力改善，中长期配置价值凸显，建议关注"优 势龙头、红利延续、强势复苏"三条主线：1）优势龙头，头部酒企份额持续提升： 贵州茅台、五粮液、山西汾酒、古井贡酒；2）红利延续，高确定性区域酒：迎驾 贡酒（洞藏大单品红利）、今世缘（江苏格局红利）等；3）强势复苏，弹性标的： 泸州老窖、水井坊、舍得酒业、老白干酒、港股珍酒李渡、酒鬼酒等。2、大众品： 青啤收购即墨黄酒，统一 25Q1 业绩亮眼，端午魔芋粽上新，大众品结构性α显 著，建议寻找强复苏与高成长两条主线：1）政策受益或复苏改善：青岛啤酒、海 天味业、新乳业、伊利股份、重庆啤酒、安琪酵母、仙乐健康、安井食品、立高食 品等，港股 H&H 国际控股等；2）高景气度或成长逻辑：盐津铺子、东鹏饮料、 燕京啤酒、珠江啤酒、三只松鼠、百润股份、有友食品等，港股农夫山泉、华润饮 料、卫龙美味等。 白酒：强化内功，蓄力改善。白酒板块从业绩窗口期进入动销淡季，在行业整体环 比降速、逐步释压的背景下，各家酒企聚 ...

证券研究报告 | 行业周报 gszqdatemark 2025 05 11 年 月 日 白酒：强化内功，蓄力改善。白酒板块从业绩窗口期进入动销淡季，在行业整体环 比降速、逐步释压的背景下，各家酒企聚焦品牌底蕴、产品结构、渠道体系、营销 打法等内功持续发力。近期今世缘召开 2024 业绩说明会，在产品体系上持续把握 结构性机会，百元大众消费趋势积极、国缘四开省内占有率与开瓶动销领先、V 系 列坚持品牌与渠道双驱动下快速放量，在渠道拓展上优化厂商关系、保持良性库 存，同时省内延续精耕攀顶策略、省外保持明显快于省内增速。在珍酒李渡近期的 2024年股东周年大会暨投资者交流会上，也重点提出将持续优化与丰富产品结构， 预计未来珍酒将推出 500-600 元价格带新品与珍十五、珍三十形成协同效应，长 期依托珍酒、李渡、湘窖等强品牌实现讲好品牌文化、多维提升品牌形象。我们认 为当下白酒行业的压力与风险已逐步释放，供给端强化经营实力的同时后续需求 端有望迎来逐级修复，中长期配置价值凸显。 啤酒饮料：青啤收购即墨黄酒多元化更进一步，统一 25Q1 业绩表现亮眼。1）啤 酒板块，本周百威亚太发布 25Q1 季报，中国区 25Q1 ...

Core Insights - Pliant Therapeutics, Inc. announced promising interim results from its Phase 1 clinical trial of PLN-101095, showing a 50% objective response rate in patients with advanced or metastatic solid tumors who are refractory to immune checkpoint inhibitors [2][5][6] Group 1: Clinical Trial Details - The trial is evaluating PLN-101095, an integrin αvβ8 and αvβ1 inhibitor, in combination with pembrolizumab in patients with ICI-refractory tumors [2][7] - Three partial responses were observed in cohort three at the highest tested dose of 1000 mg administered orally twice daily [2][5] - The trial has enrolled nine patients across three cohorts, with treatment durations of 14 days followed by combination therapy [3][5] Group 2: Efficacy Observations - Among the six patients treated at the 1000 mg BID dose, three confirmed partial responses were noted, with significant reductions in tumor sizes: 74% for NSCLC, 48% for cholangiocarcinoma, and 42% for melanoma [5][6] - Initial partial responses were observed at Week 10 for NSCLC, Week 34 for cholangiocarcinoma, and Week 18 for melanoma [5] Group 3: Safety and Tolerability - PLN-101095 was generally well tolerated across all doses tested, indicating a favorable safety profile [2][5][6] - The ongoing trial is currently enrolling the fourth cohort, which will evaluate PLN-101095 at a different dosing schedule of 1000 mg three times daily [6] Group 4: Company Background - Pliant Therapeutics is focused on developing novel therapeutics for fibrotic diseases, with PLN-101095 being a key candidate for treating solid tumors [8] - The company has received regulatory designations for its lead product candidate, bexotegrast, indicating its commitment to advancing innovative treatments [8]

Core Insights - OnKure Therapeutics, Inc. reported a net loss of $17.4 million for Q4 2024, with cash and cash equivalents of approximately $110.8 million expected to fund operations through multiple clinical readouts into Q4 2026 [1][5][10]. Financial Performance - Research and development (R&D) expenses for Q4 2024 were $14.4 million, an increase from $8.8 million in Q4 2023, primarily due to higher clinical trial and manufacturing costs [8]. - General and Administrative (G&A) expenses rose to $4.3 million in Q4 2024 from $1.1 million in Q4 2023, driven by increased personnel-related costs and consulting expenses [9]. - The net loss per share for Q4 2024 was $1.37, compared to $30.14 per share in Q4 2023 [10]. Business Highlights - OnKure is advancing three PI3Ka inhibitor programs, with one in clinical development and another expected to be announced in Q2 2025 [2]. - The PIKture-01 trial has shown encouraging preliminary safety and tolerability data for the OKI-219 monotherapy, with no dose-limiting toxicities observed [7]. - The company initiated patient dosing in Part B of the PIKture-01 trial, evaluating OKI-219 in combination with fulvestrant for metastatic breast cancer [6][7]. - A merger with Reneo Pharmaceuticals closed on October 4, 2024, along with a $65 million financing, leading to a name change and new ticker symbol "OKUR" [6]. Upcoming Milestones - Additional data from the PIKture-01 trial is expected in the second half of 2025, along with the announcement of a pan-mutant selective program [6][3]. - OnKure aims to demonstrate approximately 10-fold selectivity of its pan-mutant inhibitor against common mutations over wild type [6].

Core Viewpoint - OnKure Therapeutics, Inc. is focused on developing novel precision medicines in oncology, with a particular emphasis on targeting biologically validated drivers of cancers that are underserved by existing therapies [1]. Company Overview - OnKure Therapeutics, Inc. is a clinical-stage biopharmaceutical company listed on Nasdaq under the ticker OKUR [1]. - The company utilizes a structure- and computational chemistry-driven drug design platform to create a pipeline of tumor-agnostic candidates aimed at achieving optimal efficacy and tolerability [1]. - The lead program, OKI-219, is a selective PI3Kα inhibitor, and OnKure aims to become a leader in targeting oncogenic PI3Kα with multiple programs designed for best-in-class targeting of this key oncogene [1]. Upcoming Events - Nicholas Saccomano, Ph.D., President and CEO of OnKure, will present at the Leerink Partners Global Healthcare Conference on March 11, 2025, at 4:20 p.m. ET, with a live audio webcast available [3]. - OnKure will also participate in a fireside chat at the Stifel Targeted Oncology Forum, which will be held virtually on April 8-9, 2025 [3].

15 ult JE 相伴成长 CCB Principal Asset Mana "等" 指数 ill 察用具 B 】 4 I I A PROVED THE PERSONAL PROPERTY in 近年来,被动投资驶入"快车道" 指数类产品选择也日益丰富 而在众多指基中,有一类自带buff的存在 它既能紧跟市场的β收益 又力争创造超越指数的α收益 那就是一 】 BANGER 起突袭 或言 指数增强基金到底"强"在哪? "增强版"指数投资工具 假动 | 纯粹跟踪指数,为投资者把握市场的β收益。 在跟踪指数的基础上,通过一定策略进行增强 投资,力求超越指数创造α收益。 性品效用回族复 以跟踪沪深300、中证500、中证1000的指数增 强基金来看,近1年、3年、5年平均收益率均跑 赢了各自的跟踪标的指数,为投资者创造了可持 续的α收益,展现出良好的"超"能力。 沪深300指数增强基金业绩表现 量化模型选股,基于大数据分析科学选股 作为业内较早布局指数投资领域的基金公司之 建信基金在指数增强方面也持续发力,在 团队实力、模型搭建、产品业绩上优势显现。 HE BEATH THE SHINE HY 23.53% 25% ...